Physician profile
Andrew M Blumenthal
NPI 1962426338
$6,300.74
in general payments reported to CMS, 2019-2025
53 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $1,028 · 2021: $1,096 · 2022: $696 · 2023: $345 · 2024: $1,044 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $619.60 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $613.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $567.52 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $514.07 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $346.43 | 2019-2025 | |
| Amgen INC. | $302.87 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $282.57 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $281.22 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $236.93 | 2020-2025 | Zoryve, Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $189.46 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.71 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $154.39 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $153.86 | 2019-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $152.42 | 2019-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Blumenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.